IASLC 2019 World Conference on Lung Cancer Industry ...€¦ · 7 – 10 September 2019 •...
1
Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. 205185-IN Industry Satellite Symposium IASLC 2019 World Conference on Lung Cancer 7 – 10 September 2019 • Barcelona, Spain CHAIR Johan Vansteenkiste Professor and Head of Clinic Respiratory Oncology Unit University Hospital KU Leuven Leuven, Belgium FACULTY Benjamin Levy Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center Washington, DC, USA Associate Professor of Oncology Johns Hopkins University School of Medicine Baltimore, MD, USA Stephen Liu Department of Medicine Hematology/Oncology Georgetown University Medical Center Washington, DC, USA Tuesday, 10 September 2019 13:00 – 14:30 REDEFINING SURVIVAL EXPECTATIONS IN LUNG CANCER 12:00 – 12:05 Welcome and Introduction Johan Vansteenkiste 12:05 – 12:20 Scientific Rationale for Combining Immune Check Point Inhibitors and Chemotherapy Johan Vansteenkiste 12:20 – 12:50 Role of IO in mNSCLC Pro – Use of IO/Chemotherapy Combinations or Monotherapy in 1L Con – Preserve Option of IO Use for 2nd Line Stephen Liu – Pro Ben Levy – Con 12:50 – 13:05 Patient Cases Ben Levy 13:05 – 13:20 Beyond NSCLC – SCLC, Mesothelioma Stephen Liu 13:20 – 13:30 Q&A 13:30 Closing Remarks Johan Vansteenkiste AGENDA Chair: Johan Vansteenkiste (Belgium) This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program. Fira de Barcelona Gran Via • Hall 6, Barcelona (2005) Barcelona, Spain
Transcript of IASLC 2019 World Conference on Lung Cancer Industry ...€¦ · 7 – 10 September 2019 •...
Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. 205185-IN
Industry Satellite SymposiumIASLC 2019 World Conference on Lung Cancer7 – 10 September 2019 • Barcelona, Spain
CHAIRJohan VansteenkisteProfessor and Head of Clinic Respiratory Oncology Unit University Hospital KU Leuven Leuven, Belgium
FACULTYBenjamin LevyClinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center Washington, DC, USA Associate Professor of Oncology Johns Hopkins University School of Medicine Baltimore, MD, USA
Stephen LiuDepartment of Medicine Hematology/Oncology Georgetown University Medical Center Washington, DC, USA
Tuesday, 10 September 201913:00 – 14:30
REDEFINING SURVIVAL EXPECTATIONS IN LUNG CANCER
12:00 – 12:05 Welcome and IntroductionJohan Vansteenkiste
12:05 – 12:20 Scientific Rationale for Combining Immune Check Point Inhibitors and ChemotherapyJohan Vansteenkiste
12:20 – 12:50 Role of IO in mNSCLCPro – Use of IO/Chemotherapy Combinations orMonotherapy in 1L Con – Preserve Option of IO Use for 2nd LineStephen Liu – ProBen Levy – Con
12:50 – 13:05 Patient CasesBen Levy
13:05 – 13:20 Beyond NSCLC – SCLC, MesotheliomaStephen Liu
13:20 – 13:30 Q&A
13:30 Closing RemarksJohan Vansteenkiste
AGENDA
Chair: Johan Vansteenkiste (Belgium)
This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.
Fira de Barcelona Gran Via • Hall 6, Barcelona (2005) Barcelona, Spain
